Develops and supplies natural ingredients solutions
Prodalim is no longer just an efficient juice business. It is building a higher-margin ingredients platform, but 2025 showed that the transition still relies on external funding rather than on internally generated cash alone.
Prodalim's February 2026 raise created very large financial room relative to the December 2025 balance sheet, but the disclosed use of proceeds points first to balance-sheet repair and seasonal working-capital funding, and only second to acquisition optionality.
At the end of 2025, Solos still looks more like an expensive build-out option on the NoLo market than a business already contributing meaningfully to Prodalim’s earnings.
Prodalim's 2025 report already shows Specialty as a real earnings engine, but part of the scale management wants the market to price still comes from a Rene Laurent pro forma assumption rather than from a full reported year.
